News

This change in leadership is part of the restructuring process initiated by the company under the guidance of the board of directors to better prepare the company for

A patented, broad-spectrum liquid chemical warfare (CW) agent decontaminant, RSDL neutralizes or removes CW agents and T2 toxin from skin on contact, leaving a non-toxic residue that can

The Phase II trial, being conducted in the UK, is a multi-center, randomized, double-blind, placebo-controlled, dose response, factorial 12-arm parallel group study evaluating 120 patients equally randomized to

If successful, a broad-spectrum nanoviricide could be employed as an important Medical CounterMeasure against bio-terrorism and emerging infectious diseases such as Ebola or Marburg, and dengue. The company

The submission is based on an analysis that included 138 patients with chronic lymphocytic leukemia (CLL) who showed limited or no response to both fludarabine and alemtuzumab treatment

According to the company, duloxetine-treated patients showed greater reductions from baseline on the primary endpoint, the 24-hour average pain score on the Brief Pain Inventory (BPI), compared with

According to the company, Advance PTX is one of the first PTA balloon catheters to be coated with paclitaxel, an antiproliferative drug that has been used successfully to

The 360 patient, active comparator trial compared the efficacy and safety of NP-1 against both gabapentin and placebo. The first primary endpoint was the change in pain intensity

The investors have agreed to purchase the shares at a purchase price of $9.73 per share resulting in gross proceeds of approximately $45.5 million to Pharmasset, before deducting